At the Division of Hematology at Montefiore Medical Center, our internationally recognized hematologists and multidisciplinary experts offer the highest quality care for the management of a broad spectrum of blood disorders, including:
Anemias, acquired or hereditary hemoglobinopathies, thalassemias
White cell disorders, such as leukopenia and leukocytosis
Stem cell disorders, including:
Myeloproliferative disorders, such as polycythemia vera, essential thrombocytosis and myelofibrosis
- Platelet disorders
- Thrombosis or a blood clot in an artery
- Hemorrhagic or bleeding disorders
- Chronic leukemias, including chronic myeloid and lymphocytic leukemias
Each year, approximately 6,500 patients come to us from across the United States for consultations, advanced diagnostics and treatments, and specialty care. Our team of physicians has expertise in the diagnosis and treatment of thrombosis and in sickle-cell anemia and offers coordinated services tailored specifically for patients with these disorders.
A Distinguished Division
Montefiore Medical Center is at the forefront of prevention and treatment programs for various blood disorders. We have one of the largest thrombosis prevention and treatment programs and sickle-cell clinics in the nation.
3400 Bainbridge Avenue, 2nd Floor
Bronx, NY 10467
Montefiore and Albert Einstein College of Medicine have a long history of dedication to the care of our patients with hemoglobin disorders, particularly sickle-cell anemia. Our Sickle-Cell Program consists of several specifically designed ambulatory clinics as well as a personalized arrangement for directed care in the emergency room. Through cutting-edge research and an understanding of the latest clinical advances, we are searching for better treatments for these disorders. Patients with sickle-cell disease may schedule appointments with the Montefiore Sickle-Cell Clinic by calling the number listed above.
Thrombosis Prevention Treatment Program
The Thrombosis Prevention Treatment Program, which attracts individuals throughout the New York metropolitan area, manages bridging anticoagulation and, therefore, shortens patients' hospital stays. We provide expert inpatient and outpatient care, and we monitor the delicate transition and maintenance of therapeutic anticoagulation levels through regularly scheduled appointments. Our team collaborates with vascular surgeons, cardiologists, neurologists and obstetricians/gynecologists to treat all types of thrombosis. Patients may schedule appointments with the Thrombosis Prevention and Treatment Program by calling 718-920-6310.
Chronic Anticoagulation Program
Similarly, our Chronic Anticoagulation Program treats patients for deep venous thrombosis (DVT), pulmonary embolism, atrial fibrillation and hypercoagulable states. The program is one of the largest in the country, drawing approximately 3,000 visits each year, in addition to those in our Thrombosis Prevention Treatment Program. Patients may schedule appointments with the Chronic Anticoagulation Program by calling 718-920-6310.
Strides in Research
As our award-winning hematologists understand, groundbreaking investigations can translate to a better quality of life for those with blood disorders. Montefiore was one of the first contributors to epigenetics, the study of how allied genetic factors affect heritable defects like sickle cell. We continue to investigate sickle-cell disease through genetic mapping, microvascular studies and research. Our research team also studies the efficacy of bridging therapy to provide optimum management for patients with contradictions to anticoagulation or DVT.
Additionally, we train physicians who have finished their internal medicine training to be hematology specialists in our combined hematology/oncology fellowship program, one of the largest in the nation. Fellows receive extensive experience in diagnosis and management of a wide variety of hematological disorders and conditions. They participate in laboratory research and gain valuable clinical experience in collaboration with investigators at the forefront of research on blood diseases, obtaining the best possible treatments and therapies for our patients.